NEW YORK (GenomeWeb News) – Nanosphere today said that revenues for its third quarter rose nearly three-fold on sales of its Verigene Gram-Positive Blood Culture Test.

For the three months ended Sept. 30, the Northbrook, Ill.-based molecular diagnostics company said that revenues increased to $2.4 million from $865,000 a year ago, missing the average Wall Street expectation of $2.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.